Signal Genetics Inc (NASDAQ:SGNL) has been downgraded to Sell in a report by Zacks Investment Research today.
- Updated: October 15, 2016
Zacks Investment Research has downgraded Signal Genetics Inc (NASDAQ:SGNL) to Sell in a statement released on 10/12/2016.
On 6/23/2015, Chardan Capital released a statement for Signal Genetics Inc (NASDAQ:SGNL) bumped up the target price from $0.00 to $2.00 that suggested an upside of 0.31%.
Boasting a price of $0.50, Signal Genetics Inc (NASDAQ:SGNL) traded -3.49% lower on the day. The last closing price is down -9.08% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $0.50 and a 200-day moving average of $0.52. 23,420 shares of the stock were exchanged, down from an average trading volume of 49,860
See Chart Below
Signal Genetics Inc has a 52 week low of $0.40 and a 52 week high of $1.24 The company’s market cap is currently $0.
About Signal Genetics Inc (NASDAQ:SGNL)
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.